|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...9596979899100101102103104105...110111» |
- Halaven (eribulin mesylate) / Eisai
Enrollment closed: Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer (clinicaltrials.gov) - Aug 20, 2012
P2, N=74, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting
- | Trial completion: Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor (clinicaltrials.gov) - Aug 20, 2012
P1, N=16, Completed, Sponsor: Medinova AG
Completed --> Active, not recruiting Recruiting --> Completed
- | Trial completion: HX4-200: Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors (clinicaltrials.gov) - Aug 20, 2012
P2, N=50, Completed, Sponsor: Siemens Molecular Imaging
Recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment change: DITTO: Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging (clinicaltrials.gov) - Aug 19, 2012
P3, N=80, Recruiting, Sponsor: University of Nottingham
Active, not recruiting --> Completed N=50 --> 80
- | Enrollment open: DITTO: Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging (clinicaltrials.gov) - Aug 19, 2012
P3, N=80, Recruiting, Sponsor: University of Nottingham
N=50 --> 80 Not yet recruiting --> Recruiting
- ||||| Avastin (bevacizumab) / Roche
New P2 trial: BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - Aug 19, 2012
P2, N=56, Recruiting, Sponsor: AA Secord
- Gralise (gabapentin) / Alvogen
Trial initiation date: A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response (clinicaltrials.gov) - Aug 18, 2012
P=N/A, N=120, Recruiting, Sponsor: University of Tennessee
Not yet recruiting --> Recruiting Initiation date: Jan 2012 --> Aug 2012
- | Savella (milnacipran) / AbbVie, Pierre Fabre
Enrollment change: Savella in Treatment for Provoked Vestibulodynia (clinicaltrials.gov) - Aug 18, 2012
P3, N=31, Completed, Sponsor: University of Tennessee
Initiation date: Jan 2012 --> Aug 2012 N=20 --> 31
- Gralise (gabapentin) / Alvogen
Enrollment open: A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response (clinicaltrials.gov) - Aug 18, 2012
P=N/A, N=120, Recruiting, Sponsor: University of Tennessee
N=20 --> 31 Not yet recruiting --> Recruiting
- Choriomon (human choriomon gonadotropin (hCG)) / IBSA Institute Biochemical SA
Enrollment change: Intra-uterine Injection of Human Chorionic Gonadotrophin (hCG) Before Embryo Transfer (clinicaltrials.gov) - Aug 17, 2012
P4, N=472, Completed, Sponsor: The Egyptian IVF-ET Center
Not yet recruiting --> Recruiting N=900 --> 472
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial withdrawal, BRCA Biomarker, PARP Biomarker: Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer (clinicaltrials.gov) - Aug 17, 2012
P2, N=0, Withdrawn, Sponsor: Dana-Farber Cancer Institute
N=900 --> 472 Not yet recruiting --> Withdrawn
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment change, BRCA Biomarker, PARP Biomarker: Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer (clinicaltrials.gov) - Aug 17, 2012
P2, N=0, Withdrawn, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Withdrawn N=58 --> 0
- | cisplatin / Generic mfg., etoposide IV / Generic mfg.
New P2 trial, Metastases: First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer (clinicaltrials.gov) - Aug 16, 2012
P2, N=200, Recruiting, Sponsor: Shanghai Gynecologic Oncology Group
- ||||| HSV vaccine (GEN-003) / Genocea, Shionogi
New P1/2 trial: Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - Aug 15, 2012
P1/2, N=150, Active, not recruiting, Sponsor: Genocea Biosciences, Inc.
- Enrollment change: Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy (clinicaltrials.gov) - Aug 14, 2012
P=N/A, N=39, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=58 --> 0 N=30 --> 39
- Enrollment closed: Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy (clinicaltrials.gov) - Aug 14, 2012
P=N/A, N=39, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=30 --> 39 Recruiting --> Active, not recruiting
- | azithromycin / Generic mfg.
New P4 trial: Washington State Community Expedited Partner Treatment (EPT) Trial (clinicaltrials.gov) - Aug 13, 2012
P4, N=33222, Completed, Sponsor: University of Washington
- ||| Hepacid (pegargiminase) / Polaris Pharma
New P1 trial, Metastases: Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma (clinicaltrials.gov) - Aug 13, 2012
P1, N=89, Recruiting, Sponsor: Polaris Group
- JI-101 / Jubilant LifeSciences
Trial termination, Metastases: Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers (clinicaltrials.gov) - Aug 12, 2012
P1/2, N=19, Terminated, Sponsor: University of Utah
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Lack of drug efficacy
- JI-101 / Jubilant LifeSciences
Enrollment change, Metastases: Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers (clinicaltrials.gov) - Aug 12, 2012
P1/2, N=19, Terminated, Sponsor: University of Utah
Active, not recruiting --> Terminated; Lack of drug efficacy N=40 --> 19
- cisplatin / Generic mfg.
Enrollment closed, Metastases: Advanced Cervical Cancer Trial in India (clinicaltrials.gov) - Aug 12, 2012
P2, N=200, Active, not recruiting, Sponsor: James Graham Brown Cancer Center
N=40 --> 19 Recruiting --> Active, not recruiting
- Trial withdrawal, Biopsy: Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy (clinicaltrials.gov) - Aug 10, 2012
P3, N=0, Withdrawn, Sponsor: University of Saskatchewan
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- Enrollment change, Biopsy: Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy (clinicaltrials.gov) - Aug 10, 2012
P3, N=0, Withdrawn, Sponsor: University of Saskatchewan
Not yet recruiting --> Withdrawn N=104 --> 0
- FDG PET: ERRICC: Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy (clinicaltrials.gov) - Aug 9, 2012
P=N/A, N=148, Recruiting, Sponsor: Hospices Civils de Lyon
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Enrollment closed: AMIGOS: Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation (clinicaltrials.gov) - Aug 8, 2012
P3, N=900, Active, not recruiting, Sponsor: Yale University
N=104 --> 0 Recruiting --> Active, not recruiting
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P2 trial, BRCA Biomarker, PARP Biomarker: Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer (clinicaltrials.gov) - Aug 8, 2012
P2, N=0, Withdrawn, Sponsor: Dana-Farber Cancer Institute
- |||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) (clinicaltrials.gov) - Aug 8, 2012
P2, N=130, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 7, 2012
P2, N=50, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Suspended --> Completed
- cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial, Surgery: A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers (clinicaltrials.gov) - Aug 6, 2012
P2, N=20, Recruiting, Sponsor: Columbia University
- | pritelivir (AIC316) / AiCuris
New P2 trial: Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes (clinicaltrials.gov) - Aug 5, 2012
P2, N=91, Terminated, Sponsor: AiCuris GmbH & Co.KG
- paclitaxel / Generic mfg.
Enrollment change: Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Aug 5, 2012
P1/2, N=18, Completed, Sponsor: M.D. Anderson Cancer Center
Suspended --> Completed N=88 --> 18
- paclitaxel / Generic mfg.
Trial completion: Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Aug 5, 2012
P1/2, N=18, Completed, Sponsor: M.D. Anderson Cancer Center
N=88 --> 18 Active, not recruiting --> Completed
- | zibotentan (ZD4054) / University of Virginia, Royal Papworth Hospital, AstraZeneca
Trial termination, Metastases: ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer (clinicaltrials.gov) - Aug 2, 2012
P2, N=120, Terminated, Sponsor: AstraZeneca
Active, not recruiting --> Completed Completed --> Terminated; Primary objective of the trial was not met and so there was no benefit in collecting further information
- Dotarem (gadoterate meglumine) / Guerbet
Clinical: Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer (clinicaltrials.gov) - Aug 2, 2012
P=N/A, N=200, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- Recentin (cediranib) / AstraZeneca, RG4733 / Roche
Enrollment closed, Metastases: Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 2, 2012
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Primary objective of the trial was not met and so there was no benefit in collecting further information Recruiting --> Active, not recruiting
- | Enrollment closed: Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors (clinicaltrials.gov) - Aug 2, 2012
P2, N=20, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- Trial termination: DHEAFert2: Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF) (clinicaltrials.gov) - Aug 1, 2012
P2/3, N=5, Terminated, Sponsor: David H. Barad
Suspended --> Active, not recruiting Recruiting --> Terminated; Lack of recruitment.
- Enrollment change: DHEAFert2: Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF) (clinicaltrials.gov) - Aug 1, 2012
P2/3, N=5, Terminated, Sponsor: David H. Barad
Recruiting --> Terminated; Lack of recruitment. N=240 --> 5
- | iniparib (BSI 201) / Sanofi
Trial completion, Combination therapy, PARP Biomarker: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Jul 31, 2012
P2, N=41, Completed, Sponsor: Sanofi
N=240 --> 5 Active, not recruiting --> Completed
- Clinical: Randomized Trial of Home Versus Clinic-Based STD Testing (clinicaltrials.gov) - Jul 30, 2012
P=N/A, N=200, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- ||| Trial completion, Preclinical: POINT: A Post Marketing Assessment of Gonal f Solution for Injection in a Prefilled Pen for Follicular Stimulation in in Vitro Fertilisation/Embryo Transfer (IVF-ET) Cycles (clinicaltrials.gov) - Jul 30, 2012
P=N/A, N=61, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Recruiting --> Completed
- Trial withdrawal: A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis (clinicaltrials.gov) - Jul 30, 2012
P2, N=0, Withdrawn, Sponsor: Kaiser Permanente
Recruiting --> Completed Terminated --> Withdrawn
- Enrollment change: A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis (clinicaltrials.gov) - Jul 30, 2012
P2, N=0, Withdrawn, Sponsor: Kaiser Permanente
Terminated --> Withdrawn N=60 --> 0
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Combination therapy: PAZPET-1: [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer (clinicaltrials.gov) - Jul 30, 2012
P1, N=17, Recruiting, Sponsor: Imperial College London
N=60 --> 0 Not yet recruiting --> Recruiting
- |||||||||| Zorbtive (somatropin) / EMD Serono
New P3 trial: EMR701173_002: Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women (clinicaltrials.gov) - Jul 29, 2012
P3, N=87, Recruiting, Sponsor: Merck KGaA
- | afuresertib (LAE002) / Laekna Therap
New P1/2 trial, Combination therapy: Dose-finding Study in Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Jul 29, 2012
P1/2, N=43, Recruiting, Sponsor: Accenture
- carboplatin / Generic mfg., gemcitabine / Generic mfg.
New P1 trial, Surgery: Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer (clinicaltrials.gov) - Jul 26, 2012
P1, N=20, Recruiting, Sponsor: Case Comprehensive Cancer Center
- New P1 trial: The Effect of the Nutraceutical "Hemofix" on the Coagulation System (clinicaltrials.gov) - Jul 25, 2012
P1, N=40, Not yet recruiting, Sponsor: Hadassah Medical Organization
- davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer (clinicaltrials.gov) - Jul 25, 2012
P2, N=29, Recruiting, Sponsor: Massachusetts General Hospital
- Clinical: SEXUTOX: Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function (clinicaltrials.gov) - Jul 24, 2012
P=N/A, N=180, Recruiting, Sponsor: Centre Oscar Lambret